Rationale and study design of the INcrease of Vagal TonE in Heart Failure study: INOVATE-HF

American Heart Journal

Volumn 163, Issue 6, 2012, Pages

  Hauptman, Paul J ^a   Schwartz, Peter J ^b,c   Gold, Michael R ^d   Borggrefe, Martin ^e   Van Veldhuisen, Dirk J ^f   Starling, Randall C ^g   Mann, Douglas L ^h  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g LERNER RESEARCH INSTITUTE   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; INOTROPIC AGENT; VASODILATOR AGENT;

HEART FAILURE; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MEDICAL SOCIETY; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SINUS RHYTHM; STUDY DESIGN; VAGUS NERVE STIMULATION; VAGUS TONE;

EID: 84862514965     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.03.021     Document Type: Article

References (40)

1. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011;378:704-12.
2. Hauptman PJ, Mann DL. The vagus nerve and autonomic imbalance in heart failure: past, present, and future. Heart Fail Rev 2011;16:97-9.
3. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602. (Pubitemid 38451714)
4. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009;30:3015-26.
5. Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31. (Pubitemid 46513233)
6. Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J 2010;7:809-17.
7. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388.8-442.8.
8. Schwartz PJ. Vagal stimulation for heart diseases: from animals to men-an example of translational cardiology. Circ J 2011;75:20-7.
9. Olshansky B, Sabbah HN, Hauptman PJ, et al. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008;118:863-71.
10. Javed U, Deedwania PC. Beta-adrenergic blockers for chronic heart failure. Cardiol Rev 2009;17:287-92.
11. Desai MY, Watanabe MA, Laddu AA, et al. Pharmacologic modulation of parasympathetic activity in heart failure. Heart Fail Rev 2011;16:179-93.
12. van Veldhuisen DJ, de Graeff PA, Remme WJ, et al. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? J Am Coll Cardiol 1996;28:813-9. (Pubitemid 26348141)
13. Hauptman PJ, Kelly R. Cardiovascular drugs: digitalis. Circulation 1999;99:1265-70.
14. Li M, Zheng C, Sato T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-4. (Pubitemid 38056032)
15. Sabbah HN, Ilsar I, Zaretsky A, et al. Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 2011;16:171-8.
16. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009;2:692-9.
17. Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 2008;10:884-91.
18. De Ferrari GM, Crijns HJGM, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for heart failure. Eur Heart J 2011;32:847-55.
19. Binkley PF, Nunziata E, Haas GJ, et al. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 1991;18:464-72.
20. Schwartz PJ, DeFerrari GM. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 2011;16:101-7.
21. MortaraA,LaRovereMT, PinnaGD, et al.Arterialbaroreflexmodulation ofheart rate in chronicheart failure: clinicalandhemodynamic correlates and prognostic implications. Circulation 1997;96:3450-8.
22. Chapleau MW, Sabharwal R. Methods of assessing vagus nerve activity and reflexes. Heart Fail Rev 2011;16:109-27.
23. Bibevski S, Dunlap ME. Evidence for impaired vagus nerve activity in heart failure. Heart Fail Rev 2011;16:129-35.
24. Li W, Olshansky B. Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev 2011;16:137-45.
25. Calvillo L, Vanoli E, Andreoli E, et al. Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 2011;58:500-7.
26. Ando M, Katare RG, Kakinuma Y, et al. Efferent vagal nerve stimulation protects the heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 2005;112:164-70. (Pubitemid 40982297)
27. Cohen ML, Georgievskaya Z. Histopathology of the stimulated vagus nerve: primum non nocere. Heart Fail Rev 2011;16:163-9.
28. Agnew WF, McCreery DB. Considerations for safety with chronically implanted nerve electrodes. Epilepsia 1990;31(Suppl 2):S27-32.
29. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an Implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
30. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: The COMPASS-HF Study. J Am Coll Cardiol 2008;51:1073-9. (Pubitemid 351374766)
31. Cleland JGF, Daubert JC, Erdmann E, et al. Cardiac Resynchronization - Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49. (Pubitemid 40517094)
32. Konstam MA, Gheorghiade M, Burnett JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure-The EVEREST outcome trial. JAMA 2007;297:1319-31. (Pubitemid 46513233)
33. Cleland JGF, Charlesworth A, Lubsen J, et al. COMET investigators. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "Patient Journey") in patients with heart failure-a report from the carvedilol or metoprolol European trial (COMET). J Am Coll Cardiol 2006;47:1603-11.
34. Hwang IK, Shih WJ, DeCani JS. Group sequential designs using a family of type I error probability spending functions. Stat Med 1990; 9:1439-45.
35. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982;66:874-80. (Pubitemid 12015075)
36. Schwartz PJ, Vanoli E, Stramba-Badiale M, et al. Autonomic mechanisms and sudden death: new insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 1988;78:969-79.
37. La Rovere MT, Bigger Jr JT, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-84. (Pubitemid 28070094)
38. Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-81.
39. La Rovere MT, Bersano C, Gnemmi M, et al. Exercise-Induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction. Circulation 2002;106:945-9. (Pubitemid 34925328)
40. Anholt TA, Ayal S, Goldberg JA. Recruitment and blocking properties of the CardioFit stimulation lead. J Neural Eng 2011;8:034004.